Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(3):201-203; doi:10.1093/jnci/91.3.201
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Burke, W.
Right arrow Articles by Laya, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burke, W.
Right arrow Articles by Laya, M. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 3, 201-203, February 3, 1999
© 1999 Oxford University Press

EDITORIALS

Genetic Risk and Breast Cancer Survival: Another Link in the Chain of Evidence

Wylie Burke, Mary B. Laya

Affiliation of authors: Department of Medicine, University of Washington, Seattle.

Correspondence to: Wylie Burke, M.D., Ph.D., Department of Medicine, Box 354765, University of Washington, 4245 Roosevelt Way, N.E., Seattle, WA 98105 (e-mail: wburke@u.washington.edu).

The discovery of the BRCA1 and BRCA2 genes was an important milestone in breast cancer research. Ongoing investigation of cancer genes is sure to improve our knowledge of cancer biology and may speed development of new cancer treatments and prevention strategies. As this research effort goes forward, however, puzzling questions need to be addressed concerning the clinical effects of mutations in the BRCA1 and BRCA2 genes. We do not understand why the degree of cancer risk conferred by mutations is variable or why some mutation carriers develop breast cancer, others develop ovarian cancer, and some develop both. We do not know whether the cancers occurring in mutation carriers are essentially the same or significantly different from those occurring . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. Alsner, M. Yilmaz, P. Guldberg, L. L. Hansen, and J. Overgaard
Heterogeneity in the Clinical Phenotype of TP53 Mutations in Breast Cancer Patients
Clin. Cancer Res., October 1, 2000; 6(10): 3923 - 3931.
[Abstract] [Full Text]